CD98hc Antigen-Binding Domains for Blood-Brain Barrier Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) restricts the efficient delivery of therapeutics to the central nervous system (CNS), limiting the efficacy of recombinant proteins and antibodies, and invasive CNS injections are inefficient due to rapid cerebral spinal fluid export, while systemic high-dose administration causes unintended peripheral effects.
Innovation Solution
Antigen-binding domains, such as those specific to human CD98 heavy chain (CD98hc), are developed to cross the BBB, allowing for targeted delivery of therapeutics by binding to CD98hc and facilitating transport across the barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant proteins and antibodies are administered systemically to treat CNS diseases, then therapeutic delivery to the periphery is improved, but penetration across the BBB is insufficient
Solution Approach 1:
The patent uses CD98hc as an intermediary target on BBB endothelial cells. The antigen-binding domain specifically binds to CD98hc, utilizing this intermediary to facilitate transcytosis across the BBB. This mediator approach allows therapeutics to cross the barrier without directly overcoming the barrier's restrictive properties.
Solution Approach 2:
The invention exploits the BBB's own physiological mechanism of amino acid transport via CD98hc. By designing the antigen-binding domain to mimic amino acid transporter characteristics, the system enables self-service transport through the BBB's existing transcytotic pathway, turning the barrier's protective mechanism into a delivery vehicle.
2Reliability
If invasive CNS injections are used to deliver therapeutics directly to the brain, then BBB penetration is improved, but therapeutic retention is reduced due to rapid CSF export
Solution Approach 1:
The antigen-binding domain uses CD98hc as an intermediary to achieve BBB crossing, avoiding direct injection into the CNS. This intermediary-mediated transcytosis allows the therapeutic to enter the brain parenchyma through a controlled biological pathway rather than mechanical injection, potentially improving retention by avoiding rapid CSF clearance.
3Quantity of substance
If systemic high-dose administration is used to achieve sufficient BBB penetration, then CNS therapeutic delivery is improved, but peripheral side effects increase
Solution Approach 1:
The antigen-binding domain exhibits local quality by specifically targeting CD98hc on BBB endothelial cells. This localized binding property directs the therapeutic preferentially to the BBB interface, enabling lower systemic doses to achieve effective CNS concentrations while reducing peripheral exposure and associated side effects.
Solution Approach 2:
By using CD98hc as an intermediary target that is specifically expressed on BBB endothelial cells, the invention creates a localized delivery pathway. This intermediary approach concentrates the therapeutic effect at the BBB interface, reducing the need for high systemic doses and thereby minimizing peripheral side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances therapeutic delivery to the CNS by increasing brain:serum concentration ratios and reducing peripheral side effects, enabling effective treatment of neurological diseases.
Implementation Method 1
antigen-binding domains, such as those specific to human CD98 heavy chain (CD98hc), are developed to cross the BBB, allowing for targeted delivery of therapeutics by binding to CD98hc
Data Source
AI summary
The present disclosure is generally directed to antigen-binding domains that specifically bind to human CD98 heavy chain (CD98hc) and their use in transport across the blood brain barrier (BBB).